DOT1L and acute myeloid leukemia: DOT1L inhibitors had exhibited promise in preclinical models of AML, but ultimately the clinical applications of DOT1L inhibitor treatments were restricted due to poor responses which signal the potential benefit of multi-arresting malignant processes through combination treatments [111].